472 related articles for article (PubMed ID: 32418044)
1. Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial.
Lee HB; Han W; Kim SY; Cho N; Kim KE; Park JH; Ju YW; Lee ES; Lim SJ; Kim JH; Ryu HS; Lee DW; Kim M; Kim TY; Lee KH; Shin SU; Lee SH; Chang JM; Moon HG; Im SA; Moon WK; Park IA; Noh DY
Breast Cancer Res Treat; 2020 Jul; 182(1):97-105. PubMed ID: 32418044
[TBL] [Abstract][Full Text] [Related]
2. Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients.
Hayashi N; Tsunoda H; Namura M; Ochi T; Suzuki K; Yamauchi H; Nakamura S
Clin Breast Cancer; 2019 Feb; 19(1):71-77. PubMed ID: 30206035
[TBL] [Abstract][Full Text] [Related]
3. Prospective trial of breast MRI versus 2D and 3D ultrasound for evaluation of response to neoadjuvant chemotherapy.
Lee MC; Gonzalez SJ; Lin H; Zhao X; Kiluk JV; Laronga C; Mooney B
Ann Surg Oncol; 2015 Sep; 22(9):2888-94. PubMed ID: 25589151
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Post-Neoadjuvant Chemotherapy Image-Guided Breast Biopsy to Predict Residual Cancer.
Tasoulis MK; Lee HB; Yang W; Pope R; Krishnamurthy S; Kim SY; Cho N; Teoh V; Rauch GM; Smith BD; Valero V; Mohammed K; Han W; MacNeill F; Kuerer HM
JAMA Surg; 2020 Dec; 155(12):e204103. PubMed ID: 33026457
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of Magnetic Resonance Imaging-Guided Biopsy to Verify Breast Cancer Pathologic Complete Response After Neoadjuvant Chemotherapy: A Nonrandomized Controlled Trial.
Sutton EJ; Braunstein LZ; El-Tamer MB; Brogi E; Hughes M; Bryce Y; Gluskin JS; Powell S; Woosley A; Tadros A; Sevilimedu V; Martinez DF; Toni L; Smelianskaia O; Nyman CG; Razavi P; Norton L; Fung MM; Sedorovich JD; Sacchini V; Morris EA
JAMA Netw Open; 2021 Jan; 4(1):e2034045. PubMed ID: 33449096
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Resonance Imaging (MRI) Assessment of Residual Breast Cancer After Neoadjuvant Chemotherapy: Relevance to Tumor Subtypes and MRI Interpretation Threshold.
Kim Y; Sim SH; Park B; Lee KS; Chae IH; Park IH; Kwon Y; Jung SY; Lee S; Ko K; Kang HS; Lee CW; Lee ES
Clin Breast Cancer; 2018 Dec; 18(6):459-467.e1. PubMed ID: 29954674
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
Narui K; Ishikawa T; Oba MS; Hasegawa Y; Kaise H; Kawate T; Yamada A; Yamada K; Suzuki Y; Niikura N; Kohno N; Kimoto T; Sugae S; Kosaka Y; Miyashita M; Okamura T; Shimizu D; Tanino H; Tanabe M; Morita S; Endo I; Tokuda Y
Surg Oncol; 2020 Dec; 35():447-452. PubMed ID: 33045629
[TBL] [Abstract][Full Text] [Related]
8. Biopsy Feasibility Trial for Breast Cancer Pathologic Complete Response Detection after Neoadjuvant Chemotherapy: Imaging Assessment and Correlation Endpoints.
Rauch GM; Kuerer HM; Adrada B; Santiago L; Moseley T; Candelaria RP; Arribas E; Sun J; Leung JWT; Krishnamurthy S; Yang WT
Ann Surg Oncol; 2018 Jul; 25(7):1953-1960. PubMed ID: 29667115
[TBL] [Abstract][Full Text] [Related]
9. Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?
Heil J; Schaefgen B; Sinn P; Richter H; Harcos A; Gomez C; Stieber A; Hennigs A; Rauch G; Schuetz F; Sohn C; Schneeweiss A; Golatta M
Eur J Cancer; 2016 Dec; 69():142-150. PubMed ID: 27821317
[TBL] [Abstract][Full Text] [Related]
10. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment).
van der Noordaa MEM; van Duijnhoven FH; Loo CE; van Werkhoven E; van de Vijver KK; Wiersma T; Winter-Warnars HAO; Sonke GS; Vrancken Peeters MTFD
Breast; 2018 Aug; 40():76-81. PubMed ID: 29698928
[TBL] [Abstract][Full Text] [Related]
11. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
12. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
13. Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?
Schaefgen B; Mati M; Sinn HP; Golatta M; Stieber A; Rauch G; Hennigs A; Richter H; Domschke C; Schuetz F; Sohn C; Schneeweiss A; Heil J
Ann Surg Oncol; 2016 Mar; 23(3):789-95. PubMed ID: 26467456
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
[TBL] [Abstract][Full Text] [Related]
15. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
An YY; Kim SH; Kang BJ
World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
[TBL] [Abstract][Full Text] [Related]
16. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
17. Prediction of pathologic complete response on MRI in patients with breast cancer receiving neoadjuvant chemotherapy according to molecular subtypes.
Kim J; Han BK; Ko EY; Ko ES; Choi JS; Park KW
Eur Radiol; 2022 Jun; 32(6):4056-4066. PubMed ID: 34989844
[TBL] [Abstract][Full Text] [Related]
18. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy.
Kuerer HM; Rauch GM; Krishnamurthy S; Adrada BE; Caudle AS; DeSnyder SM; Black DM; Santiago L; Hobbs BP; Lucci A; Gilcrease M; Hwang RF; Candelaria RP; Chavez-MacGregor M; Smith BD; Arribas E; Moseley T; Teshome M; Miggins MV; Valero V; Hunt KK; Yang WT
Ann Surg; 2018 May; 267(5):946-951. PubMed ID: 28549010
[TBL] [Abstract][Full Text] [Related]
19. Residual Mammographic Microcalcifications and Enhancing Lesions on MRI After Neoadjuvant Systemic Chemotherapy for Locally Advanced Breast Cancer: Correlation with Histopathologic Residual Tumor Size.
Kim YS; Chang JM; Moon HG; Lee J; Shin SU; Moon WK
Ann Surg Oncol; 2016 Apr; 23(4):1135-42. PubMed ID: 26628432
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]